Metastatic Breast Cancer

Karen Durham never expected to be speaking on behalf of the Metastatic Breast Cancer Alliance

Debu Tripathy, editor-in-chief of CURE magazine, reports from the San Antonio Breast Breast Cancer Symposium where a study involving the PI3 kinase inhibitor pictilisib showed interesting results.

The addition of the investigational PI3K inhibitor pictilisib to the aromatase inhibitor Faslodex in patients with metastatic breast cancer yielded some intriguing findings in the FERGI study.

Debu Tripathy, MD, editor-in-chief of CURE magazine, shares the latest research in metastatic breast cancer, including targeted drugs being tested in early-phase studies that appear promising, including the PARP inhibitor veliparib, the CDK4/6 inhibitor palbociclib and the anti-angiogenesis drug trametinib.